2018 Funding Allocation

Cycle for Survival fights back against rare cancers with 100% of every dollar. This extraordinary community funds groundbreaking clinical trials, research studies, and technology development led by Memorial Sloan Kettering.

$39,000,000

Adenoid Cystic Carcinoma
Adrenocortical Carcinoma
Angiosarcoma
Bladder Cancer
Blood Cancer
Brain Cancer
Cholangiocarcinoma
Chordoma
Clear Cell Ovarian Cancer
Endometrial Cancer
Ependymoma
Esophageal Cancer
Ewing Sarcoma

Gastric Cancer
Germ Cell Tumors
GIST
Glioblastoma
Glioma
Histiocytosis
Kidney Cancer
Leiomyosarcoma
Leptomeningeal Disease
Leukemia
Liposarcoma
Liver Cancer
Lymphoma
Malignant Rhabdoid Tumors
Merkel Cell Carcinoma

Melanoma
Multiple Myeloma
Neuroblastoma
Osteosarcoma
Ovarian Cancer
Pancreatic Cancer
Pancreatic Neuroendocrine Tumors
Retinoblastoma
Rhabdomyosarcoma
Sarcoma
Stomach Cancer
Thyroid Cancer
Uterine Cancer

2018 Funding Allocation

Funded Research

Funded Research

MSK is on the frontline of the battle against rare cancers. Cycle for Survival is proud to support the advancement of comprehensive initiatives at MSK, which span across many critical areas of research.

Sloan Kettering Institute (SKI) was founded in 1945 to develop new techniques to conquer cancer. Today, SKI’s laboratories operate as the crucial experimental research arm of MSK: advancing science to help cancer patients everywhere.

Directed by Dr. Joan Massagué, SKI represents the very best of scientific inquiry. Spanning nine research programs, its staff of more than 100 investigators, 400 fellows, and 200 graduate students works together toward SKI’s collective mission: devising better ways to combat cancer. Cycle for Survival’s longtime support for SKI has propelled innovation, advanced sophisticated technologies, and bolstered infrastructure in profound ways. This year’s funding will be directed to key strategic initiatives: furthering scientists’ ability to turn ideas once considered impossible into meaningful breakthroughs for patients battling rare cancer.

The Human Oncology and Pathogenesis Program (HOPP) is MSK’s hallmark translational research program: a collaborative hub that bridges discoveries made in the lab with research leading to new and improved treatments for cancer. Cycle for Survival support has been vital to the success of this multi-disciplinary initiative—much to the benefit of patients with rare cancers.

By bringing together a brilliant collective of MSK physicians and scientists who have one foot in the laboratory and the other in clinic, HOPP serves as a unique and rapid incubator for innovative cancer-fighting strategies. Led by Dr. Charles Sawyers, the program focuses on developing novel cancer therapies, often for people with malignancies that lack effective treatments or standards of care. Cycle for Survival has been a proud, longstanding partner of this renowned program, fueling paradigm-changing research that has reshaped how rare cancers are understood and treated. HOPP researchers are among the world’s foremost experts in oncology and their findings impact the lives of patients worldwide.

Cycle for Survival is a major supporter of the groundbreaking work of the Marie-Josée and Henry R. Kravis Center for Molecular Oncology. The genomic discoveries uncovered through this revolutionary program provided answers—and fresh hope—to countless people with rare cancers.

Today, doctors target cancer cells more precisely than ever before, and work is underway to continuously improve this approach. The results of MSK-IMPACT sequencing, a technology invented at MSK—and the first such test to receive FDA authorization—can guide treatment decisions by identifying which genetic mutations are causing a person’s cancer. For patients battling rare diseases, this information can point to never-before-considered treatment options that target mutations resulting in dramatic tumor regressions or even wipe out disease. Among the leaders of this endeavor are Drs. David Solit, Marc Ladanyi, and Michael Berger. Cycle for Survival’s investment in this dynamic effort has been vital to its success and momentum: MSK just surpassed 31,000 tumors sequenced since 2014.

The Jennifer Goodman Linn Laboratory of New Drug Development in Sarcoma and Rare Cancers—named in honor of Cycle for Survival’s founder—is a powerful symbol of the movement’s commitment to attack every form of sarcoma. This support has empowered MSK’s team to move the needle with unprecedented speed.

MSK’s Sarcoma Medical Oncology Service, directed by Dr. William Tap, explores every possible option to help patients with sarcoma. Cycle for Survival has given MSK’s physician-scientists the resources to rapidly grow the arsenal of options to combat these 70+ complex diseases known to resist treatment. This includes building the world’s largest immunotherapy program focused on sarcoma: MSK is running nearly 20 clinical trials to test novel strategies against these malignancies. Scientists are also studying ways to manipulate how drugs work, and are finding ways to predict if a therapy will be effective for a patient before it’s even prescribed. Cycle for Survival backing has cemented MSK’s international reputation in sarcoma research—changing the game for people facing this challenging disease.

When diagnosed with cancer, patients often ask, “What caused my disease?” and “How can we beat it?” Cycle for Survival is fueling MSK’s computational oncology program: maximizing an abundance of “big data” to uncover the answers, guide treatment, and change the lives of patients battling rare cancers.

Scientists use clinical and molecular data, gathered over time, to predict how cancer responds to different treatments. This valuable information points future patients toward the most effective option to attack their disease so no time is wasted. Home to one of the largest data sets anywhere, MSK is taking these findings to the next level, with Dr. Sohrab Shah as the program’s inaugural Chief. Cycle for Survival is advancing MSK’s research into the microenvironment where cancer thrives and mutates. Recognizing that cancer is diverse and constantly changing, computational oncology will enable physician-scientists to see through this complexity to find new treatment options—and save lives.

If cancer is caught early, before it takes root, the likelihood of a patient’s survival can go from 5% to 90%. This is the essence of precision prevention: finding traces of disease—and stopping it in its tracks. Cycle for Survival support is propelling this ambitious MSK program, set to change the future of oncology as we know it.

Most current cancer screening tests are insufficient; many miss the first signs of disease entirely. MSK is working to change this. Led by Dr. Luis Diaz and backed by Cycle for Survival, MSK’s Precision Interception and Prevention Program is a pioneering effort to find cancer early and improve outcomes. Recent progress was made toward that goal when a clinic, run by Dr. Ross Levine, was opened for people with a blood condition that has strong links to cancer, specifically leukemia. By carefully monitoring these individuals and initiating treatment at the first sign of progression, MSK is demonstrating precision prevention in action—just the start of a pivotal new approach in cancer care.

Equinox Innovation Initiative

Equinox Innovation Initiative 

The Equinox Innovation Initiative—named in honor of Cycle for Survival’s longtime founding partner—fuels game-changing research that embodies the innovative spirit of Equinox.

These coveted grants and projects are awarded to MSK physicians and scientists annually through a highly competitive process that enables them to pursue cutting-edge research with speed and agility.

In addition to the projects listed below, the 2018 funding also supports the new Pilot Transformative Clinical Trials program, which will elevate clinical trials developed by researchers at MSK—a.k.a. “investigator-initiated” studies—and provide the financial resources necessary to launch a trial without the need for external funding from an industry or government sponsor.

2018 Funding Allocation

Select Projects

Dr. Ghassan Abou-Alfa
Gastrointestinal Oncology Service
Liver Cancer

Dr. David Abramson
Chief, Ophthalmic Oncology Service
Retinoblastoma

Dr. Nadeem Abu-Rustum
Chief, Gynecology Service
Ovarian and Uterine Cancer

Dr. Srikanth Ambati
Department of Pediatrics
Sarcoma

Dr. Cristina Antonescu
Director, Bone and Soft Tissue Pathology
Angiosarcoma, GIST, Rhabdomyosarcoma

Dr. Chris Barker
Radiation Oncology
Merkel Cell Carcinoma

Dr. Mary Baylies
Developmental Biology Program
Rhabdomyosarcoma

Dr. Robert Benezra
Cancer Biology and Genetics Program
Brain Cancer

Dr. Bernard Bochner
Urology Service
Bladder Cancer

Dr. Adrienne Boire
Brain Tumor Service
Brain Cancer

Dr. Farid Boulad
Medical Director, Pediatric Day Hospital
Acute Myeloid Leukemia

Dr. Jayanta Chaudhuri
Immunology Program
Lymphoma

Dr. Emily Cheng
HOPP
Kidney Cancer

Dr. Nai-Kong Cheung
Department of Pediatrics
Neuroblastoma

Dr. Dennis Chi
Deputy Chief, Gynecology Service
Ovarian Cancer

Dr. Daniel Coit
Gastric and Mixed Tumor Service
Merkel Cell Carcinoma

Dr. Lisa DeAngelis
Chair, Department of Neurology
Brain Cancer

Dr. Darren Feldman
Genitourinary Oncology Service
Testicular Cancer; Germ Cell Tumors

Dr. Mark Dickson
Sarcoma Service
Sarcoma

Dr. Ira Dunkel
Department of Pediatrics
Pediatric Brain Cancer

Dr. Joseph Erinjeri
Interventional Radiology Service
Interventional Radiology

Dr. Darren Feldman
Genitourinary Oncology Service
Testicular Cancer, Germ Cell Tumors

Dr. Emily Foley
Cell Biology Program
Ovarian and Uterine Cancer

Dr. Sergio Giralt
Chief, Adult Bone Marrow Transplant Service
Multiple Myeloma

Dr. Michael Glickman
Immunology Program
Bladder Cancer

Dr. Mrinal Gounder
Sarcoma Medical Oncology Service
Chordoma

Dr. Rachel Grisham
Gynecologic Medical Oncology Service
Ovarian Cancer

Dr. Alan Hanash
Bone Marrow Transplant Service
Stem Cell Transplantation

Dr. John Healey
Chief, Orthopaedic Service
Bone Cancer

Dr. Daniel Heller
Molecular Pharmacology Program
Nanomedicine

Dr. Martee Hensley
Gynecologic Medical Oncology Service
Gynecologic Sarcomas

Dr. Alan Ho
Head and Neck Oncology Service
Head and Neck Cancers; Thyroid Cancer

Dr. Christine Iacobuzio-Donahue
Associate Director for Translational Research, Rubenstein Center for Pancreatic Cancer Research
Pancreatic Cancer

Dr. Andrew Intlekofer
Lymphoma Service
Lymphoma

Dr. Yelena Janjigian
Chief, Gastrointestinal Oncology Service
Esophogeal Cancer

Dr. William Jarnagin
Chief, Hepatopancreatobiliary Service
Gallbladder cancer

Dr. Alexandra Joyner
Developmental Biology Program
Pediatric Brain Cancer

Dr. Yasmin Khakoo
Director, Child Neurology Program
Pediatric Brain Tumors

Dr. Virginia Klimek
Leukemia Service
Myelodysplastic Syndrome

Dr. Andrew Koff
Molecular Biology Program
Brain Tumors and Liposarcoma

Dr. Jason Konner
Chief, Medical Oncology at MSK Monmouth
Clear Cell Ovarian Cancer

Dr. Andrew Kung
Chair, Department of Pediatrics
Pediatric Cancer

Dr. Brian Kushner
Department of Pediatrics
Neuroblastoma

Dr. Michael La Quaglia
Chief, Pediatric Surgical Service
Sarcomas

Dr. Marc Ladanyi
Chief Attending, Department of Pathology; HOPP
Sarcoma

Dr. Heather Landau
Myeloma Service; Bone Marrow Transplant Service
Multiple Myeloma

Dr. Nikoletta Lendvai
Myeloma Service, Department of Medicine
Multiple Myeloma

Dr. Scott Lowe
Chair, Cancer Biology & Genetics Program
Cholangiocarcinoma

Dr. Vicky Makker
Gynecologic Medical Oncology Service
Gynecologic Cancers

Dr. Paul Meyers
Department of Pediatrics
Sarcoma; Rhabdomyosarcoma

Dr. Robert Motzer
Genitourinary Oncology Service
Kidney Cancer

Dr. Eileen O’Reilly
Associate Director for Clinical Research, Center for Pancreatic Cancer Research
Pancreatic Cancer

Dr. Kenneth Offit
Chief, Clinical Genetics Service
Ovarian Cancer

Dr. Luis Parada
Director, Brain Tumor Center
Brain Cancer

Dr. John Petrini
Director, Functional Genomics Initiative; Chair, Molecular Biology
Myodysplasia

Dr. Michael Postow
Melanoma and Immunotherapeutics Service
Melanoma

Dr. Diane Reidy Lagunes
Gastrointestinal Oncology Service
Pancreatic Neuroendocrine Tumors and Adrenocortical Carcinoma

Dr. Neal Rosen
Molecular Pharmacology Program
Cholangiocarcinoma

Dr. Jonathan Rosenberg
Chief, Genitourinary Medical Oncology Service
Bladder and Kidney Cancer

Dr. Alexander Rudensky
Ludwig Center for Cancer Immunotherapy
Immunotherapy Research

Dr. David Scheinberg
Chair, Molecular Pharmacology Program
Mesotheolioma

Dr. Neal Shukla
Department of Pediatrics
Pediatric Lymphoma

Dr. Mariel (Molly) Smith
Department of Pediatrics
Rhabdomyosarcoma

Dr. David Solit
Director, CMO; Make An Impact
DNA Sequencing

Dr. Amber Simpson
Memorial Hospital Research Laboratories
Cholangiocarcinoma

Dr. Samuel Singer
Chief, Gastric and Mixed Tumor Service
Sarcoma

Dr. Viviane Tabar
Chair, Department of Neurosurgery
Brain Cancer

Dr. Martin Tallman
Chief Attending, Leukemia Service
Myeloid Leukemia and Acute Lymphoblastic Leukemia

Dr. Tanya Trippett
Department of Pediatrics
Pediatric Blood Cancers

Dr. Andrea Ventura
Cancer Biology & Genetics Program
Brain Tumors

Dr. Aaron Viny
Leukemia Service
Acute myeloid leukemia

Dr. Leonard Wexler
Department of Pediatrics
Rhabdomyosarcoma

Dr. Jedd Wolchok
Chief, Melanoma & Immunotherapeutics Service
Immunotherapy

Dr. Anas Younes
Chief Attending, Lymphoma Service
Hodgkin and Non-Hodgkin Lymphoma

December Challenge

The December Challenge:
Molecular Oncology

This past December, the Cycle for Survival community raised $2 million to purchase a DNA sequencer and fund genomic profiling. This technology and approach is how MSK doctors and researchers investigate the drivers behind each person’s cancer. DNA sequencing provides key insights that can be used to determine the best treatment options.

The machine is now at home in an MSK lab. It is faster, more efficient, cost effective, and more precise than ever before.

Every participant who received a donation from five donors during the month of December had their names displayed in the lab with the new sequencer.

cfs19_decchallengeposter.png

Download more information

2017 Funding Allocation

Download PDF  >

2016 Funding Allocation

Download PDF  >

2015 Funding Allocation

Download PDF  >

2014 Funding Allocation

Download PDF  >